C15orf32: A Potential Drug Target and Biomarker (G145858)

Target Name: C15orf32

NCBI ID: G145858

C15orf32

Other Name(s): CO032_HUMAN | Chromosome 15 open reading frame 32 | chromosome 15 putative open reading frame 32 | Uncharacterized protein C15orf32

C15orf32: A Potential Drug Target and Biomarker

C15orf32 (CO032_HUMAN), a protein encoded by human gene C15orf32, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization in the human body make it an attractive target for drug development.

The protein encoded by C15orf32 is a cytoplasmic protein that is predominantly localized to the endoplasmic reticulum (ER) and cytoplasm. It has a molecular weight of approximately 41 kDa and a pre-folding length of 22 amino acids. C15orf32 is a single-pass transmembrane protein that consists of a unique transmembrane region, a cytoplasmic region, and an N-terminal extracellular domain.

The cytoplasmic region of C15orf32 is characterized by a characteristic 伪-helical structure that gives it a unique flexibility and stability in the cytoplasm. This region is also involved in the protein-protein interaction, as it contains several potential interaction sites that can participate in protein -protein binding.

One of the unique features of C15orf32 is its subcellular localization in the ER and cytoplasm. The ER is a specialized protein-folding machine that plays a crucial role in the folding and storage of proteins. The cytoplasm is the fluid that surrounds the cells and is responsible for maintaining the cell's shape, as well as providing the space for various cellular processes. The ER and cytoplasm are distinct cellular compartments that are separated by the ER-membrane, which is a thin layer of lipid bilayer membrane that separates the cytoplasm from the ER.

C15orf32's subcellular localization in the ER and cytoplasm make it an attractive target for drug development because it is more likely to be targeted by small molecules, which are often used as lead compounds for drug development. Additionally, its unique structure and subcellular localization may also make It is more stable and less susceptible to degradation, which can improve its stability and persistence in the body.

C15orf32 has been shown to play a role in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that C15orf32 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting C15orf32 may be an effective way to treat these cancers.

In addition to its potential as a drug target, C15orf32 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that C15orf32 is downregulated in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. This suggests that Targeting C15orf32 may be an effective way to treat neurodegenerative diseases, such as Alzheimer's disease.

In conclusion, C15orf32 is an attractive drug target and biomarker due to its unique structure and subcellular localization in the ER and cytoplasm. Its potential as a drug target for various diseases, including cancer and neurodegenerative disorders, makes it an important target for future drug development . Additionally, its potential as a biomarker for various diseases, including cancer and neurodegenerative disorders, makes it an important tool for the diagnosis and treatment of these diseases.

Protein Name: Chromosome 15 Putative Open Reading Frame 32

The "C15orf32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C15orf32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets